{
    "abstractText": "In the published article, there was an error in Figure 8 as published. The results of a mistaken measurement were shown in Figures 8A, B. Consequently, the numerical values of the t-test comparing the phospho-tau/total tau ratios in the control and STZ treated groups in EXP1 and EXP2 are inadequate. The corrected Figure 8 and its corrected caption appear below: Furthermore, the name and catalogue number of the phospho-tau antibody in the Western Blot section was erroneous. As such, a correction has been made to \u201cMethods and materials, Western Blot.\u201d The sentence previously stated: \u201cMembranes were incubated with primary antibodies against PHF1 (sc515013, 1: 1,000, Santa Cruz Biotechnology, Santa Cruz, CA, United States). . .\u201d The corrected sentence appears below: \u201cMembranes were incubated with primary antibodies against PHF-13 (sc32275, 1: 1,000, Santa Cruz Biotechnology, Santa Cruz, CA, United States). . .\u201d The numerical values of the multivariate analysis of variance results were also inadequate. Therefore, a correction has been made to \u201cResults, Multivariate analysis of variance.\u201d The sentence previously stated: OPEN ACCESS",
    "authors": [
        {
            "affiliations": [],
            "name": "Attila G\u00e1sp\u00e1r"
        },
        {
            "affiliations": [],
            "name": "Barbara Hutka"
        },
        {
            "affiliations": [],
            "name": "Aliz Judit Ernyey"
        },
        {
            "affiliations": [],
            "name": "Brigitta Tekla Tajti"
        },
        {
            "affiliations": [],
            "name": "Bence Tam\u00e1s Varga"
        },
        {
            "affiliations": [],
            "name": "Zolt\u00e1n S\u00e1ndor Z\u00e1dori"
        },
        {
            "affiliations": [],
            "name": "Istv\u00e1n Gyerty\u00e1n"
        },
        {
            "affiliations": [],
            "name": "Arjan Blokland"
        }
    ],
    "id": "SP:9294ae336869f9735a2e4cf519c58f15c25bbe7d",
    "references": [],
    "sections": [
        {
            "text": "Corrigendum: Intracerebroventricularly Injected Streptozotocin Exerts Subtle Effects on the Cognitive Performance of Long-Evans Rats\nAttila G\u00e1sp\u00e1r, Barbara Hutka, Aliz Judit Ernyey, Brigitta Tekla Tajti, Bence Tam\u00e1s Varga, Zolt\u00e1n S\u00e1ndor Z\u00e1dori and Istv\u00e1n Gyerty\u00e1n*\nDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary"
        },
        {
            "heading": "KEYWORDS",
            "text": "Alzheimer disease model, STZ icv., cognitive test battery, learning impairment, \u03b2amyloid, phospho-tau\nA Corrigendum on Intracerebroventricularly injected streptozotocin exerts subtle effects on the cognitive performance of long-evans rats\nby G\u00e1sp\u00e1r A, Hutka B, Ernyey AJ, Tajti BT, Varga BT, Z\u00e1dori ZS and Gyerty\u00e1n I (2021) Front. Pharmacol. 12:662173. doi: 10.3389/fphar.2021.662173\nIn the published article, there was an error in Figure 8 as published. The results of a mistaken measurement were shown in Figures 8A, B. Consequently, the numerical values of the t-test comparing the phospho-tau/total tau ratios in the control and STZ treated groups in EXP1 and EXP2 are inadequate. The corrected Figure 8 and its corrected caption appear below:\nFurthermore, the name and catalogue number of the phospho-tau antibody in the Western Blot section was erroneous. As such, a correction has been made to \u201cMethods and materials, Western Blot.\u201d The sentence previously stated:\n\u201cMembranes were incubated with primary antibodies against PHF1 (sc515013, 1:\n1,000, Santa Cruz Biotechnology, Santa Cruz, CA, United States). . .\u201d\nThe corrected sentence appears below: \u201cMembranes were incubated with primary antibodies against PHF-13 (sc32275, 1:\n1,000, Santa Cruz Biotechnology, Santa Cruz, CA, United States). . .\u201d\nThe numerical values of the multivariate analysis of variance results were also inadequate. Therefore, a correction has been made to \u201cResults, Multivariate analysis of variance.\u201d The sentence previously stated:"
        },
        {
            "heading": "OPEN ACCESS",
            "text": ""
        },
        {
            "heading": "EDITED AND REVIEWED BY",
            "text": "Arjan Blokland, Maastricht University, Netherlands\n*CORRESPONDENCE Istv\u00e1n Gyerty\u00e1n, gyertyan.istvan@med.semmelweisuniv.hu"
        },
        {
            "heading": "SPECIALTY SECTION",
            "text": "This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology\nRECEIVED 12 December 2022 ACCEPTED 16 December 2022 PUBLISHED 05 January 2023"
        },
        {
            "heading": "CITATION",
            "text": "G\u00e1sp\u00e1r A, Hutka B, Ernyey AJ, Tajti BT, Varga BT, Z\u00e1dori ZS and Gyerty\u00e1n I (2023), Corrigendum: Intracerebroventricularly Injected Streptozotocin Exerts Subtle Effects on the Cognitive Performance of LongEvans Rats. Front. Pharmacol. 13:1122260. doi: 10.3389/fphar.2022.1122260"
        },
        {
            "heading": "COPYRIGHT",
            "text": "\u00a9 2023 G\u00e1sp\u00e1r, Hutka, Ernyey, Tajti, Varga, Z\u00e1dori and Gyerty\u00e1n. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permittedwhich does not comply with these terms.\nFrontiers in Pharmacology frontiersin.org01\nTYPE Correction PUBLISHED 05 January 2023 DOI 10.3389/fphar.2022.1122260\n\u201cThe difference between the control and STZ groups was significant in EXP2 (Wilks \u03bb = 0.391, F(4,13) = 5.054; p = 0.011) whereas it was not significant in EXP1 (Wilks \u03bb = 0.750, F(4,7) = 0.583; p = 0.685298344).\u201d\nThe corrected sentence appears below: \u201cThe difference between the control and STZ groups was significant in EXP2 (Wilks \u03bb = 0.397, F(4,13) = 4,931; p = 0.012) whereas it was not significant in EXP1 (Wilks \u03bb = 0.583, F(4,6) = 1.072; p = 0.446).\u201d\nThe authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way.\nThe original article has been updated. This is a provisional file, not the final typeset article\nPublisher\u2019s note\nAll claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may bemade by its manufacturer, is not guaranteed or endorsed by the publisher.\nFIGURE 8 The effect of icv. STZ or citrate buffer (control) treatment on the tissue protein levels of phospho-Tau (A,B) and \u03b2-amyloid (C,D) in EXP1 (A,C) and EXP2 (B,D)measured by Western blot. Means \u00b1 SEM values are shown. There was no significant difference between the groups in phospho-tau/ tau ratio in EXP1 (unpaired t-test: t (14) = \u22120.19, ns) (A) whereas a trend for an increase in the STZ group can be seen in EXP2 (unpaired t-test: t (22) = \u22122.012, p = 0.06) (B) Also, there was no significant difference in \u03b2-amyloid level in EXP1 (unpaired t-test: t (13) = \u22121.13, ns) (C) while significantly elevated \u03b2-amyloid level was found in the STZ-treated group in EXP2 (unpaired t-test: t (20) = \u22122.45, p < 0.05 (D) *<0.05, #<0.10.\nFrontiers in Pharmacology frontiersin.org02\nG\u00e1sp\u00e1r et al. 10.3389/fphar.2022.1122260"
        }
    ],
    "title": "Corrigendum: Intracerebroventricularly Injected Streptozotocin Exerts Subtle Effects on the Cognitive Performance of Long-Evans Rats",
    "year": 2022
}